Screening for potential adjuvants administered by the pulmonary route for tuberculosis vaccines

AAPS Journal

Volumn 11, Issue 1, 2009, Pages 139-147

  Wang, Chenchen ^a   Muttil, Pavan ^a   Lu, Dongmei ^a,c   Beltran Torres, Adela Ayulia ^b   Garcia Contreras, Lucila ^a   Hickey, Anthony J ^a  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MORELOS   (Mexico)

^c PFIZER INC   (United States)

Author keywords

Adjuvants; Cytotoxicity; Immunostimulant; Microparticles; Pulmonary

Indexed keywords

ALKALINE PHOSPHATASE; BCG VACCINE; LACTATE DEHYDROGENASE; MURAMYL DIPEPTIDE; N ACETYL BETA GLUCOSAMINIDASE; POLYGLACTIN; TREHALOSE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME ACTIVITY; ENZYME RELEASE; HUMAN; HUMAN CELL; LUNG ALVEOLUS MACROPHAGE; MICROENCAPSULATION; PARTICLE SIZE; SPRAY DRYING;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL LINE; CELL SURVIVAL; DRUG COMPOUNDING; DRUG DISCOVERY; HUMANS; LACTIC ACID; MACROPHAGE ACTIVATION; MACROPHAGES, ALVEOLAR; MICE; MICROSCOPY, ELECTRON, SCANNING; MONOCYTES; PARTICLE SIZE; POLYGLYCOLIC ACID; TREHALOSE; TUBERCULOSIS VACCINES;

EID: 65549165981     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-009-9089-0     Document Type: Article

References (38)

1. WHO. World Health Organization Report 2008 - global tuberculosis control - surveillance, planning, financing. Retrieved on 31 December 2008 from http://www.who.int/tb/publications/global_report/2008/en/index.html.
2. No authors listed. Fifteen year follow up of trial of BCG vaccines in south India for tuberculosis prevention. Tuberculosis Research Centre (ICMR), Chennai. Indian J. Med. Res. 110:56-69 (1999).
3. M. Gonzalez-Juarrero, O. C. Turner, J. Turner, P. Marietta, J. V. Brooks, and I.M. Orme. Temporal and spatial arrangement of lymphocytes within lung granulomas induced by aerosol infection with Mycobacterium tuberculosis. Infect. Immun. 69(3):1722-1728 (2001).
4. L. A. Van Pinxteren, J. P. Cassidy, B. H. Smedegaard, E. M. Agger, and P. Andersen. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur. J. Immunol. 30(12):3689-3698 (2000).
5. P. Salgame. Host innate and Th1 responses and the bacterial factors that control Mycobacterium tuberculosis infection. Curr. Opin. Immunol. 17(4):374-380 (2005).
6. P. J. Brennan. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis (Edinb). 83(1-3):91-97 (2003).
7. I. Sugawara, T. Udagawa, S. C. Hua, M. Reza-Gholizadeh, K. Otomo, Y. Saito, and H. Yamada. Pulmonary granulomas of guinea pigs induced by inhalation exposure of heat-treated BCG Pasteur, purified trehalose dimycolate and methyl ketomycolate. J. Med. Microbiol. 51(2):131-137 (2002).
8. R. Ryll, K. Watanabe, N. Fujiwara, H. Takimoto, R. Hasunuma, Y. Kumazawa, M. Okada, and I. Yano. Mycobacterial cord factor, but not sulfolipid, causes depletion of NKT cells and upregulation of CD1d1 on murine macrophages. Microbes Infect. 3(8):611-619 (2001).
9. R. Oiso, N. Fujiwara, H. Yamagami, S. Maeda, S. Matsumoto, S. Nakamura, N. Oshitani, T. Matsumoto, T. Arakawa, and K. Kobayashi. Mycobacterial trehalose 6,6′-dimycolate preferentially induces type 1 helper T cell responses through signal transducer and activator of transcription 4 protein. Microb. Pathog. 39(1-2):35-43 (2005).
10. G. Lemaire, J. P. Tenu, J. F. Petit, and E. Lederer. Natural and synthetic trehalose diesters as immunomodulators. Med. Res. Rev. 6(3):243-274 (1986).
11. F. Audibert, L. Chedid, P. Lefrancier, J. Choay, and E. Lederer. Relationship between chemical structure and adjuvant activity of some synthetic analogues of N-acetyl-muramyl-L-alanyl-D-isoglutamine (MDP). Ann. Immunol. (Paris). 128C(3):653-661 (1977).
12. M. Parant, F. Parant, L. Chedid, A. Yapo, J. F. Petit, and E. Lederer. Fate of the synthetic immunoadjuvant, muramyl dipeptide (14C-labelled) in the mouse. Int. J. Immunopharmacol. 1(1):35-41 (1979).
13. H. S. Warren, F. R. Vogel, and L. A. Chedid. Current status of immunological adjuvants. Annu. Rev. Immunol. 4:369-388 (1986).
14. L. Garcia-Contreras, Y. L. Wong, P. Muttil, D. Padilla, J. Sadoff, J. Derousse, W. A. Germishuizen, S. Goonesekera, K. Elbert, B.R. Bloom, R. Miller, P. B. Fourie, A. Hickey, and D. Edwards. Immunization by a bacterial aerosol. Proc. Natl. Acad. Sci. U. S. A. 105(12):4656-4660 (2008).
15. R. J. Pettis, I. Hall, D. Costa, and A. J. Hickey. Aerosol delivery of muramyl dipeptide to rodent lungs. AAPS PharmSci. 2(3):E25 (2000).
16. S. Nagao, M. Nakanishi, H. Kutsukake, K. Yagawa, S. Kusumoto, T. Shiba, A. Tanaka, and S. Kotani. Macrophages are stimulated by muramyl dipeptide to induce polymorphonuclear leukocyte accumulation in the peritoneal cavities of guinea pigs. Infect. Immun. 58(2):536-542 (1990).
17. Markers of Cellular and Biochemical Response, in Biologic Markers in Pulmonary Toxicology, National Research Council (US) Subcommittee on Pulmonary Toxicology, National Academy of Sciences National Academy Press. pp. 105-132 (1989).
18. P. Andersen. TB vaccines: Progress and problems. Trends Immunol. 22(3):160-168 (2001).
19. M. Wilson, R. Seymour, and B. Henderson. Bacterial perturbation of cytokine networks. Infect. Immun. 66(6):2401-2409 (1998).
20. I. M. Orme, and A. M. Cooper. Cytokine/chemokine cascades in immunity to tuberculosis. Immunol. Today. 20(7):307-312 (1999).
21. D. M. Mosser. The many faces of macrophage activation. J. Leukoc. Biol. 73(2):209-212 (2003).
22. R. Vehring. Pharmaceutical particle engineering via spray drying. Pharm. Res. 25(5):999-1022 (2008).
23. D. H. Bowden, and I. Y. Adamson. Pathways of cellular efflux and particulate clearance after carbon instillation to the lung. J. Pathol. 143(2):117-125 (1984).
24. E. G. Langenback, E. H. Bergofsky, J. G. Halpern, and W. M. Foster. Supramicron-sized particle clearance from alveoli: Route and kinetics. J. Appl. Physiol. 69(4):1302-1308 (1990).
25. A. Tanaka, S. Nagao, R. Nagao, S. Kotani, T. Shiba, and S. Kusumoto. Stimulation of the reticuloendothelial system of mice by muramyl dipeptide. Infect. Immun. 24(2):302-307 (1979).
26. C. J. Riendeau, and H. Kornfeld. THP-1 cell apoptosis in response to Mycobacterial infection. Infect. Immun. 71(1):254-259 (2003).
27. H. Schwende, E. Fitzke, P. Ambs, and P. Dieter. Differences in the state of differentiation of THP-1 cells induced by phorbol ester and 1,25-dihydroxyvitamin D3. J. Leukoc. Biol. 59(4):555-561 (1996).
28. R. Hernandez-Pando, and G.A. Rook. The role of TNF-alpha in T-cell-mediated inflammation depends on the Th1/Th2 cytokine balance. Immunology. 82(4):591-595 (1994).
29. J. L. Flynn, M. M. Goldstein, J. Chan, K. J. Triebold, K. Pfeffer, C. J. Lowenstein, R. Schreiber, T. W. Mak, and B. R. Bloom. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity. 2(6):561-572 (1995).
30. V. Kindler, A. P. Sappino, G. E. Grau, P. F. Piguet, and P. Vassalli. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell. 56(5):731-740 (1989).
31. T. Ulrichs, and S. H. Kaufmann. New insights into the function of granulomas in human tuberculosis. J. Pathol. 208(2):261-269 (2006).
32. M. L. Arcila, M. D. Sanchez, B. Ortiz, L. F. Barrera, L. F. Garcia, and M. Rojas. Activation of apoptosis, but not necrosis, during Mycobacterium tuberculosis infection correlated with decreased bacterial growth: Role of TNF-alpha, IL-10, caspases and phospholipase A2. Cell. Immunol. 249(2):80-93 (2007).
33. D. Lu, L. Garcia-Contreras, D. Xu, S. Kurtz, J. Liu, M. Braunstein, D. N. McMurray, A. J. Hickey. Poly (lactide-co-glycolide) microspheres in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen 85B. Pharm. Res. 24(10):1834-1843 (2007).
34. L. Holten-Andersen, T. M. Doherty, K. S. Korsholm, and P. Andersen. Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect. Immun. 72(3):1608-1617 (2004).
35. A. W. Olsen, A. Williams, L. M. Okkels, G. Hatch, and P. Andersen. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect. Immun. 72(10):6148-6150 (2004).
36. D. Yildiz, Y.S. Liu, N. Ercal, and D.W. Armstrong. Comparison of pure nicotine- and smokeless tobacco extract-induced toxicities and oxidative stress. Arch. Environ. Contam. Toxicol. 37(4):434-439 (1999).
37. S. Suarez, M. Kazantseva, M. Bhat, D. Costa, and A. J. Hickey. The influence of suspension nebulization or instillation on particle uptake by guinea pig alveolar macrophages. Inhal. Toxicol. 13(9):773-788 (2001).
38. L. Mu, and S. S. Feng. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J. Control. Release. 86(1):33-48 (2003).